白人活检证实的高血压肾硬化症临床表型与长期预后
挪威1988-2012年4920例因CKD转诊肾活检患者中,918例(19%)活检证实为高血压肾硬化症(动脉肾硬化)。临床标准敏感性低(0.17)、特异性高(0.94),常见误诊为肾小球肾炎(22%)和间质性肾炎(14%)。动脉肾硬化症患者ESRD和死亡风险与肾小球肾炎、间质性肾炎等无差异,但糖尿病肾病风险高2倍。
要点
- 临床标准诊断高血压肾硬化症敏感性仅0.17,特异性0.94,易漏诊
- 活检证实者常见蛋白尿(57%)、低eGFR(44%)、血尿(34%)等非典型表现
- 动脉肾硬化症ESRD和死亡风险与肾小球肾炎、间质性肾炎相当
核心结论
- 动脉肾硬化症是高危疾病,常呈非典型表型,现有临床标准准确性低。
研究设计与样本
- 纳入1988-2012年挪威因CKD转诊肾活检且临床表现符合但非主要怀疑高血压肾硬化的患者4920例,随访至2013年。
主要发现
- 918例(19%)活检证实为动脉肾硬化症。
- 活检指征最常见为蛋白尿(57%)、低eGFR(44%)、血尿(34%)或其组合。
- 多因素logistic回归显示动脉肾硬化症与较高年龄、男性、无糖尿病、较高血压、较低蛋白尿、无血尿显著相关(P<0.01)。
- BMI、胆固醇、HDL胆固醇、eGFR与动脉肾硬化症无显著相关(P>0.05)。
- 符合临床标准者活检诊断最常见为动脉肾硬化症(40%)、肾小球肾炎(22%)、间质性肾炎(14%)。
关键数值与推荐
- 临床标准诊断高血压肾硬化症敏感性0.17,特异性0.94。
- 动脉肾硬化症患者ESRD和死亡风险与肾小球肾炎、间质性肾炎或其他相关诊断无差异(P>0.1)。
- 糖尿病肾病患者ESRD和死亡风险高2倍(P<0.001)。
临床怎么用
- 临床诊断高血压肾硬化症需警惕低敏感性,非典型表现(蛋白尿、血尿)时应考虑肾活检明确诊断。
- 动脉肾硬化症患者预后与肾小球肾炎、间质性肾炎相当,应积极管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hypertensive nephrosclerosis is considered the second most common cause of end-stage renal disease (ESRD), but it is still an insufficiently studied and controversial disease entity. More information on the phenotype and prognosis is needed to improve clinical diagnostics and treatment. METHODS: We included all Norwegian patients with chronic kidney disease (CKD) referred for kidney biopsy between 1988 and 2012 whose clinical presentation was consistent with, but not primarily suspicious for, hypertensive nephrosclerosis (n = 4920); follow-up continued until 2013. RESULTS: A total of 918 patients (19%) had biopsy-verified hypertensive nephrosclerosis (i.e., arterionephrosclerosis). Their most common biopsy indications were proteinuria (57%), low estimated glomerular filtration rate (eGFR) (44%), hematuria (34%), or combinations of these indications. Multivariable logistic regression analysis revealed that arterionephrosclerosis was significantly associated with higher age, male sex, not having diabetes, higher blood pressure, lower proteinuria, and not having hematuria (P < 0.01 for all). Body mass index, cholesterol, high-density lipoprotein cholesterol, and eGFR were not significantly associated with arterionephrosclerosis (P > 0.05 for all). The most common biopsy-verified diagnoses in patients fulfilling the clinical criteria for hypertensive nephrosclerosis were arterionephrosclerosis (40%), glomerulonephritis (22%), and interstitial nephritis (14%), reflecting that the criteria had low sensitivity (0.17) and high specificity (0.94). ESRD and mortality risks did not differ in patients with arterionephrosclerosis compared to patients with glomerulonephritis, interstitial nephritis, or other relevant diagnoses (P > 0.1 for both), whereas patients with diabetic kidney disease had a 2-fold higher risk (P < 0.001 for both). CONCLUSION: Arterionephrosclerosis is a high-risk disease, often with an atypical phenotype with proteinuria and hematuria contributing to low accuracy for current clinical criteria for hypertensive nephrosclerosis.
引用
- Øvrehus MA, Oldereid TS, Dadfar A, et al. Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis. Kidney Int Rep. 2019. PMID: 32154455. doi:10.1016/j.ekir.2019.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。